The global PD-1/PD-L1 inhibitors market is projected to witness remarkable growth over the next decade, with an estimated market size of USD 49.5 billion in 2023. According to recent forecasts, the market is expected to expand at a compound annual growth rate (CAGR) of 9.6%, reaching a valuation of USD 123.3 billion by 2033.
PD-1/PD-L1 inhibitors are a class of immunotherapy drugs used to treat various cancers by blocking the interaction between the programmed death-1 (PD-1) receptor and its ligand PD-L1, thereby boosting the immune system’s ability to fight cancer cells. The rising prevalence of cancer globally and the growing adoption of immunotherapies are key factors driving market growth.
Key Factors Fueling Market Expansion:
- Increasing Prevalence of Cancer: The global rise in cancer cases, coupled with the demand for more effective treatments, is propelling the demand for PD-1/PD-L1 inhibitors, which have shown promising results in various cancer types, including lung, bladder, and melanoma.
- Growing Adoption of Immunotherapy: Immunotherapy is rapidly becoming a preferred treatment option due to its ability to target cancer cells with fewer side effects compared to traditional treatments, driving the demand for PD-1/PD-L1 inhibitors.
- Ongoing Research and Development: Continuous advancements in cancer immunotherapy research and the development of new PD-1/PD-L1 inhibitor drugs are further enhancing the treatment landscape and contributing to market growth.
As pharmaceutical companies invest in the development of innovative cancer therapies, the PD-1/PD-L1 inhibitors market is poised to experience substantial growth, offering significant potential for improving cancer treatment outcomes globally.
This substantial growth reflects the expanding role of PD-1/PD-L1 inhibitors in oncology, driven by their effectiveness in treating various cancers through immune checkpoint inhibition. The increasing prevalence of cancer, ongoing advancements in immunotherapy, and rising investment in research and development are key factors contributing to the market’s expansion.
The PD-1/PD-L1 inhibitors market is gaining momentum as healthcare providers and researchers continue to explore new therapeutic applications and enhance treatment outcomes. This growth highlights the significant impact of innovative immunotherapies on cancer treatment strategies.
The increased R&D activities are projected to generate considerable growth potential for key competitors in the Global PD-1/PD-L1 Inhibitors Industry. Market participants, for example, are expanding their spending in research and development to fulfil increased demand.
- Anti-PD-1 and anti-PD-L1 immunotherapies for patients with metastatic melanomas are being developed by researchers at Johns Hopkins Kimmel Cancer Centre. The therapy’s purpose is not to directly destroy cancer cells, but to disrupt a route that protects tumour cells from immune system components capable of fighting cancer.
PD-1/PD-L1 Inhibitors Market Key Takeaways
- The hospital pharmacies category is predicted to have a considerable market share of 48.3% over the projection period because of its vast client base, rising healthcare expenses, and rising cases of diseases such as lung and bladder cancer, melanoma, Hodgkin lymphoma, and others.
- By 2033, the United States is expected to generate US$ 23.4 billion in revenue. The government is increasing funding and support for cancer drug development. A boom in market research and development for new and innovative pharmaceuticals is also supporting regional growth.
- China is expected to be a lucrative market, with a 14.0% annual growth rate. The sale of approved therapies and the increasing occurrence of blood-related tumours are two of the key causes for the significant rise of the PD-1 and PD-L1 inhibitors market. Vendors’ rising patient support programmes are moving the market in this region ahead.
- Pembrolizumab is expected to grow at an 8.7% annual pace throughout the forecast period, reaching a significant market share of 49.5% in 2022. Pembrolizumab’s use has expanded due to its established efficacy in treating FDA-approved indications such as head and neck squamous cell cancer (HNSCC), non-small cell lung cancer (NSCLC), melanoma, and others.
- Tamil Nadu in India is developing a treatment policy to identify 66.0% of cancer patients in the first and second stages by 2030, allowing for proper treatment. As a result, such a policy is expected to fuel demand for PD-1 inhibitor drugs, propelling the growth of the segment over the forecast period.
Manufacturers are Constantly Evolving Business Models
Companies in the Global PD-1/PD-L1 Inhibitors Industry are moderately competitive by nature, with several key players present. These players are part of several strategic alliances. The agreement and system automation speed up the manufacturer’s strategy to capitalize on market share and capture a sizable market share.
PD-1/PD-L1 Inhibitors Market Key Players:
- Akeso Inc.
- Alphamab Oncology
- Amgen Inc.
- AstraZeneca Plc
- BeiGene Ltd.
- Bristol Myers Squibb Co.
- Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
- Eli Lilly and Co.
- Others
Latest Developments in the PD-1/PD-L1 Inhibitors Market
- Novartis International AG acquired The Medicines Company in January 2020. This acquisition aided Novartis in using a vaccine-like approach to treat the world’s leading cause of mortality and disability.
- Merck announced the FDA approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, in October 2021. Patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (Combined Positive Score [CPS] 1) as determined by an FDA-approved test are given the therapy.
A Old Full Report Analysis Click Here
PD-1/PD-L1 Inhibitors Market Segment by Category
By Product:
- Nivolumab
- Pembrolizumab
- Atezolizumab
- Avelumab
- Durvalumab
By Indication:
- Melanoma
- Non-Small Cell Lung Cancer (NSCLC)
- Renal Cell Carcinoma (RCC)
- Head and Neck Squamous Cell Cancer (HNSCC)
- Bladder Cancer
- Merkel Cell Carcinoma (MCC)
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
